An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses.
Sponsor: Janssen Scientific Affairs, LLC
A EARLY_PHASE1 clinical study on Ichthyosis, this trial is completed. The trial is conducted by Janssen Scientific Affairs, LLC and has accumulated 13 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Mar 2025 — Present [monthly]
Completed EARLY_PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Completed EARLY_PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
Status: Active Not Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting EARLY_PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting EARLY_PHASE1
▶ Show 8 earlier versions
-
May 2023 — Apr 2024 [monthly]
Active Not Recruiting EARLY_PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2022 — May 2023 [monthly]
Recruiting EARLY_PHASE1
-
May 2021 — May 2022 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Mar 2021 — Apr 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Oct 2020 — Dec 2020 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Scientific Affairs, LLC
- Northwestern University
For direct contact, visit the study record on ClinicalTrials.gov .